Insider buying last 90 days
No open-market insider purchases were filed for GHRS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GHRS insider filing, plotted on the chart in Gekko.Open GHRS in Gekko
NASDAQ: GHRS
GH Research (GHRS) Stock Analysis & Forecast
Oct 12 close
$20.02−1.09 (−5.2%)
Gekko Brief
AI summaryOct 12 closeThis week GH Research presented clinical trial results for its GH001-TRD-201 and GH001-BD-202 studies at the 39th European College of Neuropsychopharmacology annual meeting in Munich, with three trial posters scheduled for presentation on October 11, 2026. Separate commentary also pointed to trading systems reacting to volatility in GHRS, flagging weak near- and mid-term sentiment alongside a strong long-term outlook. Despite the clinical presentations, shares fell 5.2% on the day to close at $20.02.
The stock sits between its 50-day average of $26.91 and 200-day average of $21.21, with a 52-week range of $12.04 to $31.44. Monthly returns show a 1-month decline of 26.4% and a 3-month decline of 25.2%, though the 6-month return stands at 22.5% and the 1-year return at 51.9%. The GekkoIndex reads 72.8, placing GHRS in the Buying zone, while the price sits 30.9% below the Gekko Fair Value of $28.99.
Over the next 20 trading days, the main event is the earnings report due 5 November 2026, 24 days away, which falls inside that window; the prior report on 6 August 2026 beat estimates with an EPS of -0.23 against a -0.29 estimate and produced a 3.9% reaction. No insider, Congress or unusual options activity appears in the current 90-day and 30-day windows respectively. Seasonally, the next 20 trading days have averaged a 12.9% move over 5 years, rising in 3 of them, a pattern worth noting given the typical 20-day move of 12.6% for this stock.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
GH Research price vs fair value
Close $20.02200-day averageGekko Fair Value $28.99
GH Research quick facts
- Market cap
- $1.37B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.99
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.33
- Volume
- 229,658 avg 305,915
- 1-year return
- +51.9%
- Typical daily move
- ±7%
- Typical 20-day move
- ±12.6%
- 50-day average
- $26.91
- 200-day average
- $21.21
- Next earnings
- Nov 5
- Shares outstanding
- 68.64M
GH Research swing-trade checklist
GH Research scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $20.02 sits between the 50-day ($26.91) and 200-day ($21.21) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
72.8, Buying
Reading 72.8 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
30.9% below
Price is 30.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+12.9% on average
From this point in the calendar, the next 20 trading days averaged +12.9% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
GH Research stock chart and price history
GH Research closed at $20.02 on Oct 12, 2026, +51.9% over the past year, inside a 52-week range of $12.04 to $31.44.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −26.4%
- 3 months
- −25.2%
- 6 months
- +22.5%
- 1 year
- +51.9%
The full GHRS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GHRS in Gekko
Follow GH Research through every session
Put GHRS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GHRS in GekkoFree for 7 days. No credit card required.
About GH Research
GH Research works on experimental treatments for psychiatric and neurological illness, with its efforts built around a compound called 5-MeO-DMT. The main focus is treatment-resistant depression, a condition that has not responded to standard therapies, and the company is best known for its inhalable candidate aimed at these patients.
That inhalable program, GH001, is the furthest along, having gone through two early-stage trials and a combined Phase 1/2 study in people with treatment-resistant depression. Behind it sit two earlier-stage candidates still in preclinical testing: GH002, given by injection, and GH003, delivered through the nose. Both are being explored for use across a range of psychiatric and neurological conditions, extending the company's work beyond the lead depression program.
GH Research was established in 2018 and operates out of Dublin, Ireland. Its shares trade on the NASDAQ under the ticker GHRS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- ghres.com
GH Research GekkoIndex: the smart money zone
GH Research’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 72.8, in the Buying zone, up 0.6 points over five sessions.
72.8Buying
Up 0.6 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying (current zone) | 37 | −0.8% | +6.7% |
| Accumulation | 155 | +3.4% | +9.4% |
| Neutral | 440 | +1.2% | +4.6% |
| Distribution | 34 | 0.0% | +3.6% |
| Selling | 16 | +0.8% | +4.4% |
Average GHRS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the GHRS price, zone by zone.Track GHRS in Gekko
Is GH Research stock overvalued? Gekko Fair Value
GH Research trades 30.9% below Gekko Fair Value of $28.99, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what GH Research shares are worth, recalculated every trading day.
$28.99
Gekko Fair Value, Oct 10, 2026
30.9% Undervalued
At the end of Aug 2026 the price was 28.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open GHRS in Gekko
GH Research insider and Congress trading
No open-market insider purchases were filed for GH Research, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GHRS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GHRS, plotted on the chart in Gekko.Open GHRS in Gekko
GH Research earnings: next date and track record
GH Research reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 5, 2026
24 days away
- EPS estimate
- −$0.31
7 of 8reports beat the EPS estimate
±2.5%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.23 est −$0.29 | — | +3.9% |
| May 14, 2026 | −$0.31 est −$0.26 | — | −2.2% |
| Mar 5, 2026 | −$0.22 est −$0.27 | — | −0.4% |
| Nov 6, 2025 | −$0.23 est −$0.24 | — | −0.7% |
| Aug 7, 2025 | −$0.15 est −$0.21 | — | +2.1% |
| May 8, 2025 | −$0.19 est −$0.35 | — | +1.1% |
| Feb 27, 2025 | −$0.17 est −$0.22 | — | −7.7% |
| Nov 14, 2024 | −$0.23 est −$0.24 | — | −1.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
GH Research stock forecast and analyst price targets
Analysts’ average 12-month price target for GH Research is $42.89, +114.2% from the last close, from 8 firms rating the stock in the last 90 days.
$42.89consensus 12-month target, +114.2% from the last close
Now $20.02Avg $42.89
Low $39High $65
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 31 | Wells Fargo | $44 | +119.8% |
| Aug 10 | H.C. Wainwright | $65 | +224.7% |
| Aug 6 | Guggenheim | $40 | +99.8% |
| Aug 6 | Canaccord Genuity | $39 | +94.8% |
| Aug 6 | Cantor Fitzgerald | $40 | +99.8% |
+6.7%average 20-day move after past Buying readings
+12.9%average move over the next 20 trading days in the last 5 years
±7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
GH Research seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, GH Research averaged +12.9% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.6% | 3 of 5 |
| Next 10 trading days | −2.5% | 2 of 5 |
| Next 15 trading days | +11.5% | 3 of 5 |
| Next 20 trading days | +12.9% | 3 of 5 |
| Next 30 trading days | +16.0% | 3 of 5 |
For scale, GHRS’s typical 20-trading-day move in either direction is about 12.6%.
GH Research market cap and key statistics
GH Research’s market cap is $1.37B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.37B
- EPS, TTM
- −$0.99
- Gekko Fair Value
- $28.99
Trading
- Volume
- 229,658
- Avg volume, 20 days
- 305,915
- 52-week high
- $31.44
- 52-week low
- $12.04
- Shares outstanding
- 68.64M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -18.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.33
- Typical daily move
- ±7%
- Typical 20-day move
- ±12.6%
GH Research stock news this week
Coverage of GH Research this week reads neutral: 1 positive, 5 neutral and 0 negative headlines.
- GH Research PLC (1KA.HM) stock price, news, quote and historyYahoo Finance Australia, Oct 12
- Trading Systems Reacting to (GHRS) VolatilityStock Traders Daily, Oct 12
- GH Research PLC (GHRS) options chainYahoo Finance UK, Oct 9
- GH Research to Showcase GH001 Clinical Trial Findings at ECNP 2026 in MunichKalkine Media, Oct 9
- Three trial posters from GH Research (GHRS) are scheduled for October 11, 2026, in Munich.Stock Titan, Oct 9
- GH Research PLC (1KA.HM) balance sheetYahoo Finance UK, Oct 9
GH Research peers
GH Research’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
GH Research stock FAQ
What is GH Research’s market cap?
GH Research’s market cap is $1.37B at the Oct 12, 2026 close of $20.02, with 68.64M shares outstanding.
What is the GH Research stock forecast?
The consensus analyst 12-month price target for GH Research is $42.89, +114.2% from the last close. Of the 8 firms that rated the stock in the last 90 days, 8 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is GH Research stock overvalued or undervalued?
On Gekko’s estimate GH Research is undervalued: the Oct 12, 2026 close of $20.02 is 30.9% below Gekko Fair Value of $28.99. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does GH Research report earnings next?
GH Research is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of −$0.31 per share. GH Research beat the earnings estimate in 7 of its last 8 reports, moving 2.5% on average across the report.
What is GH Research’s 52-week high and low?
GH Research’s 52-week high is $31.44 and its 52-week low is $12.04; it closed at $20.02 on Oct 12, 2026, +51.9% over the past year.
Is GH Research stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See GH Research the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.